Keytruda? Opdivo? Teva And mAbxience Broaden Partnership With PD-1 Biosimilar
Teva Broadens Partnership To Include Biosimilar Checkpoint Inhibitor
Teva is continuing along its well-trodden path of partnered biosimilar assets, striking a further agreement with Spanish develop mAbxience that could be for the development of either pembrolizumab or nivolumab.
